Drug Profile

Tumour lysate particle only vaccine - Orbis Health Solutions

Alternative Names: TLPO vaccine

Latest Information Update: 21 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orbis Health Solutions
Developer Cancer Insight; Elios Therapeutics
Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

29 Nov 2023 Phase-II clinical trials in Solid tumours (Second-line therapy or greater, Early-stage disease, Late-stage disease, Adjunctive treatment) in USA (Intradermal) (NCT06175221)
30 Mar 2021 Phase-I/II trial is still ongoing for Malignant melanoma (In adults, In the elderly, Late-stage disease, Prevention of relapse) in USA (Parenteral) (NCT02301611)
04 Jan 2019 Tumour lysate, particle only (TLPO) vaccine licensed to Perseus

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com